A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19

NCT05216601 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Vaccine

Interventions

BIOLOGICAL: MVC-COV1901
BIOLOGICAL: MVC-COV1901(Beta)-15
BIOLOGICAL: MVC-COV1901(Beta)-25

Sponsor

Medigen Vaccine Biologics Corp.